REG - Roquefort Theraptcs. - Notice of AGM - Correction

Roquefort TherapeuticsAnnouncement

13/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220613:nRSM5577Oa&default-theme=true

RNS Number : 5577O  Roquefort Therapeutics PLC  13 June 2022

13 June 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Notice of Annual General Meeting - Correction

 

Following the announcement made on 7 June 2022 giving notice of the Annual
General Meeting (the "AGM") of the Company to be held on 30 June 2022, and the
publication and despatch of a circular to shareholders containing notice of
the resolutions to be considered at the AGM (the "Notice") and form of proxy,
it has come to the attention of the Company that the Notice contains a
typographical error.

 

The explanatory notes at paragraph 2 contained on page 7 of the Notice
incorrectly states that "Pursuant to regulation 41 of the Uncertificated
Securities Regulations 2001 (as amended) and paragraph 18(c) of the Companies
Act 2006 (Consequential Amendments) (Uncertificated Securities) Order 2009,
the Company specifies that only those members registered on the Company's
register of members at close of business on 27 June 2022 shall be entitled to
attend, speak and vote at the Annual General Meeting (or if the meeting is
adjourned, those members registered on the register of members of the Company
not later than 48 hours before the time fixed for the adjourned meeting).".
The Notice should instead state that "…the Company specifies that only those
members registered on the Company's register of members at 10am on 28 June
2022 shall be entitled to attend, speak and vote at the Annual General Meeting
(or if the meeting is adjourned, those members registered on the register of
members of the Company not later than 48 hours before the time fixed for the
adjourned meeting).".

 

As this was a clerical error, no new Notice will be posted to shareholders;
however, a copy of the corrected Notice is available on the following page of
the Company's website:

 https://www.roquefortplc.com/category/shareholder-documents/
(https://www.roquefortplc.com/category/shareholder-documents/)

 

-Ends-

 

Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is a pre-clinical biotech company
focused on developing first in class Midkine targeting drugs for the treatment
of cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGRGDLDUBDGDD